{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:05:20Z","timestamp":1787879120016,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LTGY23H160007"],"award-info":[{"award-number":["LTGY23H160007"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07540-w","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T02:44:04Z","timestamp":1766457844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinicopathologic features and therapeutic outcomes in EGFR\/ALK-aberrations NSCLC with histologic transformation"],"prefix":"10.1186","volume":"24","author":[{"given":"Kaibo","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dujiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-8804","authenticated-orcid":false,"given":"Yanjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"3","key":"7540_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"7540_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10066","key":"7540_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments [J]. Lancet. 2017;389(10066):299\u2013311.","journal-title":"Lancet"},{"key":"7540_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","volume":"61","author":"PT Harrison","year":"2020","unstructured":"Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer [J]. Semin Cancer Biol. 2020;61:167\u201379.","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"7540_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/cncr.34757","volume":"129","author":"M Herrera-Juarez","year":"2023","unstructured":"Herrera-Juarez M, Serrano-Gomez C, Bote-De-Cabo H, et al. Targeted therapy for lung cancer: beyond EGFR and ALK [J]. Cancer. 2023;129(12):1803\u201320.","journal-title":"Cancer"},{"issue":"8","key":"7540_CR6","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers [J]. Clin Cancer Res. 2013;19(8):2240\u20137.","journal-title":"Clin Cancer Res"},{"issue":"75","key":"7540_CR7","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors [J]. Sci Transl Med. 2011;3(75):75ra26.","journal-title":"Sci Transl Med"},{"key":"7540_CR8","doi-asserted-by":"crossref","unstructured":"Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer [J]. Nat Commun. 2015;6(1).","DOI":"10.1038\/ncomms7377"},{"issue":"suppl1","key":"7540_CR9","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors [J]. Ann Oncol. 2018;29(suppl1):i10\u20139.","journal-title":"Ann Oncol"},{"issue":"Pt 2","key":"7540_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.semcancer.2022.03.006","volume":"86","author":"X Yin","year":"2022","unstructured":"Yin X, Li Y, Wang H, et al. Small cell lung cancer transformation: from pathogenesis to treatment [J]. Semin Cancer Biol. 2022;86(Pt 2):595\u2013606.","journal-title":"Semin Cancer Biol"},{"key":"7540_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.05.006","volume":"94","author":"G Giaccone","year":"2023","unstructured":"Giaccone G, He Y. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer [J]. Semin Cancer Biol. 2023;94:1\u201310.","journal-title":"Semin Cancer Biol"},{"issue":"26","key":"7540_CR12","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.2016.71.9096","volume":"35","author":"JK Lee","year":"2017","unstructured":"Lee JK, Lee J, Kim S, et al. Clonal history and genetic predictors of transformation into Small-Cell carcinomas from lung adenocarcinomas [J]. J Clin Oncol. 2017;35(26):3065\u201374.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7540_CR13","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-Mutant lung cancers at risk for histologic transformation and inferior clinical outcomes [J]. J Thorac Oncol. 2019;14(10):1784\u201393.","journal-title":"J Thorac Oncol"},{"key":"7540_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.05.006","volume":"94","author":"G Giaccone","year":"2023","unstructured":"Giaccone G, He Y. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer [J]. Sem Cancer Biol. 2023;94:1\u201310.","journal-title":"Sem Cancer Biol"},{"issue":"7","key":"7540_CR15","doi-asserted-by":"publisher","first-page":"105326","DOI":"10.1016\/j.esmoop.2025.105326","volume":"10","author":"C Catania","year":"2025","unstructured":"Catania C, Liu SV, Garassino M, et al. Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study [J]. ESMO Open. 2025;10(7):105326.","journal-title":"ESMO Open"},{"key":"7540_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2022.02.006","volume":"166","author":"D Fujimoto","year":"2022","unstructured":"Fujimoto D, Akamatsu H, Morimoto T, et al. Histologic transformation of epidermal growth factor receptor-mutated lung cancer [J]. Eur J Cancer. 2022;166:41\u201350.","journal-title":"Eur J Cancer"},{"issue":"4","key":"7540_CR17","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/JCO.18.01585","volume":"37","author":"N Marcoux","year":"2019","unstructured":"Marcoux N, Gettinger SN, O\u2019kane G, et al. EGFR-Mutant adenocarcinomas that transform to Small-Cell lung cancer and other neuroendocrine carcinomas: clinical outcomes [J]. J Clin Oncol. 2019;37(4):278\u201385.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7540_CR18","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1016\/j.jtho.2024.09.655","volume":"19","author":"L Chen","year":"2024","unstructured":"Chen L, Zhang XH, Mao ZJ, et al. P3.13D.10 clinical outcomes of transformed Small-Cell lung cancer versus extensive primary Small-Cell lung cancer [J]. J Thorac Oncol. 2024;19(10):S363\u20134.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"7540_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00432-025-06194-x","volume":"151","author":"O Yildiz","year":"2025","unstructured":"Yildiz O, Eryilmaz MK, Gurbuz AF, et al. Small cell lung cancer differentiation in patients with driver mutant non-small cell lung cancer: a single center experience [J]. J Cancer Res Clin Oncol. 2025;151(7):199.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"7540_CR20","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jtho.2023.10.012","volume":"19","author":"J Huang","year":"2024","unstructured":"Huang J, Osarogiagbon RU, Giroux DJ, et al. The international association for the study of lung cancer staging project for lung cancer: proposals for the revision of the N descriptors in the forthcoming ninth edition of the TNM classification for lung cancer [J]. J Thorac Oncol. 2024;19(5):766\u201385.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"7540_CR21","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1111\/cas.16192","volume":"115","author":"A Shiba-Ishii","year":"2024","unstructured":"Shiba-Ishii A, Takemura N, Kawai H, et al. Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: current knowledge of genetic changes and molecular mechanisms [J]. Cancer Sci. 2024;115(7):2138\u201346.","journal-title":"Cancer Sci"},{"issue":"9","key":"7540_CR22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, et al. The 2015 world health organization classification of lung tumors: impact of Genetic, clinical and radiologic advances since the 2004 classification [J]. J Thorac Oncol. 2015;10(9):1243\u201360.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"7540_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cac2.12023","volume":"40","author":"WCC Tan","year":"2020","unstructured":"Tan WCC, Nerurkar SN, Cai HY, et al. Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy [J]. Cancer Commun (Lond). 2020;40(4):135\u201353.","journal-title":"Cancer Commun (Lond)"},{"key":"7540_CR24","doi-asserted-by":"publisher","first-page":"175883592513690","DOI":"10.1177\/17588359251369038","volume":"17","author":"X Li","year":"2025","unstructured":"Li X, Ding K, Liu D, et al. Histologic transformation after targeted therapy resistance in driver gene-positive NSCLC: mechanisms and therapeutic challenges [J]. Ther Adv Med Oncol. 2025;17:17588359251369038.","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"7540_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ajpath.2022.03.007","volume":"192","author":"M Masawa","year":"2022","unstructured":"Masawa M, Sato-Yazawa H, Kashiwagi K, et al. REST inactivation and coexpression of ASCL1 and POU3F4 are necessary for the complete transformation of RB1\/TP53-Inactivated lung adenocarcinoma into neuroendocrine carcinoma [J]. Am J Pathol. 2022;192(6):847\u201361.","journal-title":"Am J Pathol"},{"issue":"19","key":"7540_CR26","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1111\/1759-7714.14144","volume":"12","author":"S Wang","year":"2021","unstructured":"Wang S, Xie T, Hao X, et al. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma [J]. Thorac Cancer. 2021;12(19):2585\u201393.","journal-title":"Thorac Cancer"},{"issue":"10","key":"7540_CR27","doi-asserted-by":"publisher","first-page":"e25046","DOI":"10.1097\/MD.0000000000025046","volume":"100","author":"L Lai","year":"2021","unstructured":"Lai L, Meng W, Wei J, et al. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports [J]. Med (Baltim). 2021;100(10):e25046.","journal-title":"Med (Baltim)"},{"issue":"21","key":"7540_CR28","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, Janne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-Mutated advanced NSCLC [J]. N Engl J Med. 2023;389(21):1935\u201348.","journal-title":"N Engl J Med"},{"key":"7540_CR29","doi-asserted-by":"publisher","first-page":"102820","DOI":"10.1016\/j.critrevonc.2019.102820","volume":"146","author":"SE Rebuzzi","year":"2020","unstructured":"Rebuzzi SE, Alfieri R, La Monica S, et al. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives [J]. Crit Rev Oncol Hematol. 2020;146:102820.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"7540_CR30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata AN, Niederst MJ, Archibald HL, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor Inhibition [J]. Nat Med. 2016;22(3):262\u20139.","journal-title":"Nat Med"},{"key":"7540_CR31","doi-asserted-by":"crossref","unstructured":"Chunhui Zheng M, Yanbing Liu, Msca Xue\u2019er, Wang M, Bi Z, Mda P, Qiu, Mda G, Qiao L, Li MSCE. Ningning Luo, MSCE, Yongsheng Wang, MDA,*. Clinical ef!cacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer:a experimental single-arm phase II clinical trial pilot study [J]. Int J Surg. 2024;110(3):1527\u201336.","DOI":"10.1097\/JS9.0000000000001011"},{"key":"7540_CR32","unstructured":"Hidekazu Oyoshi 1, Junyan Du 2,3,\u2020, Sakai SA 2,3, Yamashita R. 2,4,5, Masayuki Okumura 1, Atsushi Motegi 1,6, Hidehiro Hojo 1,6, Masaki Nakamura 1,6, Hidenari Hirata 1,6, Hironori Sunakawa 7, Daisuke Kotani 8, Tomonori Yano 7, Takashi Kojima 8, Yuka Nakamura 9, Motohiro Kojima 9, Ayako Suzuki 5, Junko Zenkoh 5, Katsuya Tsuchihara 2,3, Tetsuo Akimoto 1,6, Atsushi Shibata 10,*, Yutaka Suzuki 5,*, Shun-Ichiro Kageyama 1,4,6,*. Comprehensive single-cell analysis demonstrates radiotherapy-induced infiltration of macrophages expressing immunosuppressive genes into tumor in esophageal squamous cell carcinoma [J]. Sci Adv. 2023;9(50):eadh9069."}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07540-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07540-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07540-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T15:40:44Z","timestamp":1769442044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07540-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7540"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07540-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for the use of patient specimens was obtained from each participant. The study protocols were approved by the Ethics Committee of Zhejiang Cancer Hospital (Hangzhou, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}